“A significant event”: CBD-based pharma drug Epidiolex presented to FDA for approval

Analysts have estimated that Epidiolex could be a $1 billion drug for GW Pharmaceuticals.

A CBD-based pharmaceutical drug in development is one more step closer to potential FDA approval.

Earlier this week, London-based GW Pharmaceuticals plc, which operates in the United States as Greenwich Biosciences, wrapped up its New Drug Application for Epidiolex, a formulation of the cannabis compound cannabidiol (CBD) for the treatment of seizures associated with two specific types of epilepsy: Lennox-Gastaut syndrome and Dravet syndrome.

“The submission is a significant event,” said Steve Schultz, a GW spokesman.

Read More at TheCannabist.co